Novavax Inc. Revenue 2010–2025
Novavax Inc. annual/quarterly revenue history and growth rate from 2010 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Novavax Inc. revenue for the quarter ending March 31, 2026 was 139.5 M, a 79.07% decrease year-over-year.
- Novavax Inc. revenue for the twelve months ending March 31, 2026 was 1.1 B, a 42.90% increase year-over-year.
- Novavax Inc. annual revenue for 2025 was 1.1 B, a 64.69% increase from 2024.
- Novavax Inc. annual revenue for 2024 was 682.2 M, a 30.65% decrease from 2023.
- Novavax Inc. annual revenue for 2023 was 983.7 M, a 50.36% decrease from 2022.
- Novavax Inc. annual revenue for 2022 was 2.0 B.
Novavax Inc. (NVAX) — Frequently Asked Questions
Novavax Inc. (NVAX) is a publicly traded US company. It has a market capitalization of $1.51B. In fiscal 2025 it reported revenue of $1.12B and net income of $440M. Explore NVAX's stock price, financial statements, earnings history, margins and key ratios below.
What is Novavax Inc.'s market cap?
Novavax Inc. (NVAX) has a market capitalization of $1.51B.
What is the NVAX stock price?
NVAX trades at $8.70 (+1.64% on the day).
How much revenue does Novavax Inc. make?
Novavax Inc. reported revenue of $1.12B in fiscal 2025.
Is NVAX profitable?
In fiscal 2025, Novavax Inc. reported net income of $440M.